Hybrid artificial liver support system for treatment of severe liver failure

Table 1 Clinical feature of patients.

	HALSS group (n = 10)	Plasmapheresis group (n = 10)	Control group (n = 10)
Sex
Male	3	2	3
Female	7	8	7
Average age (yr)	39.5	41.5	40.5
Range (yr)	35-56	27-60	30-58
Encephalopathy	4	2	1
Ascites	8	6	7
Hepatorenal syndrome	9	7	7
Biochemical index
Tbil (mmol/L)	499.5±25.1	519.4±137.5	496.3±93.2
Dbil (mmol/L)	227.5±19.0	269.6±118.4	286.5±107.3
ALT (U/L)	347.6±126.5	303.2±139.4	336.2±139.6
ALB (g/L)	29.8±0.4	29.9±5.3	30.9±5.3
PTA	17.5±1.2	22.8±6.5	21.5±4.4

Tbil: Total bilirubin, Dbil: Direct bilirubin, ALT: Alanine aminotransferase, PTA: Prothrombin activity.

Table 2 General condition of patients at two weeks after treatment.

	HALSS group (n = 10)		Plasmapheresis group (n = 10)		Control group (n = 10)
	Pre-	Post-	Pre-	Post-	Pre-	Post-
Encephalopathy	4	2	2	2	1	2
Ascites	8	3	6	3	7	9
Hepatorenal syndrome	9	3	7	3	7	9